COVID-19: Rapid Antibody Screening & Saliva Testing
THE NEW YORK TIMES: Just Spit and Wait – New Coronavirus Test Offers Advantage
Press Release
Published: May 15, 2020
Published: May 15, 2020
The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.
Mayors from the participating communities released this joint statement about the project:
“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”
Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:
- Wednesday, May 20 – Draper
- Thursday, May 21 – Riverton
- Tuesday, May 26 – Draper
- Thursday, May 28 – Bluffdale
- Friday, May 29 – Vineyard
Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.
The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.
Mayors from the participating communities released this joint statement about the project:
“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”
Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:
- Wednesday, May 20 – Draper
- Thursday, May 21 – Riverton
- Tuesday, May 26 – Draper
- Thursday, May 28 – Bluffdale
- Friday, May 29 – Vineyard
Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.
FDA Authorized Saliva Testing will be used to Confirm Active COVID-19 Infection
In addition, RSS will randomly administer a saliva-based DNA test to some test subjects. Draper-based Spectrum Solutions manufactures the saliva tests that detect active COVID-19 infection, rather than detecting antibodies. Any person who tests positive for antibodies will also receive the saliva test to confirm active COVID-19 infection. The testing will be conducted in full compliance with FDA and CLIA requirements. The test results will not be diagnostic but are designed to provide valuable data about the COVID-19 infection rate. Check on the availability of diagnostic at-home COVID-19 testing options using saliva by visiting Spectrum’s website.
© Spectrum Solutions™ SDNA-1000 Only EUA Authorized Saliva Collection Device for COVID-19 Testing | Photo Credit: Leslie Titus Bryant
Spectrum
in the News
Spectrum
in the News
Noninvasive
Saliva Diagnostics
This changes everything!
Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant. Engineered to lead the saliva collection industry, the BioMAX™ delivers the safest and most robust biosample for the earliest detection and diagnosis of disease and infection.
Since 2020 and the COVID-19 pandemic, Spectrum’s saliva collection system not only introduced, it continues to expand the molecular diagnostics industry and its understanding of the opportunities saliva offers patients, providers, and laboratories.
- Pain-free, non-invasive, & safe
- Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
- First EUA-authorized saliva collection device for COVID-19 testing
- No temperature-controlled storage or transport of collected biosamples
- A single saliva sample provides opportunity for multiple tests
- Months and years of post-collection stability with no degradation in sample efficacy (depending on the analyte)
- Maintain critical bio-sample consistency
- Mitigates any risk of viral infection throughout the testing process
- Delivers the highest levels of testing accuracy using qualified extraction chemistries
Noninvasive
Saliva Diagnostics
This changes everything!
Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant. Engineered to lead the saliva collection industry, the BioMAX™ delivers the safest and most robust biosample for the earliest detection and diagnosis of disease and infection.
Since 2020 and the COVID-19 pandemic, Spectrum’s saliva collection system not only introduced, it continues to expand the molecular diagnostics industry and its understanding of the opportunities saliva offers patients, providers, and laboratories.
Outside-of-the-Box Thinking, Inside-of-the-Box Innovation
Anywhere from customized testing solutions to new medical science product innovations–we’re here to help.